Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39612 |
BTK-IN-5
|
||
BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases, respiratory diseases, inflammation, and diabetes. | |||
T62153 |
JAK3/BTK-IN-5
|
||
JAK3/BTK-IN-5 是一种 JAK3/BTK 的有效抑制剂。其中 BTK 和 JAK3 是自身免疫性疾病的两个关键的靶点。同时抑制 BTK/JAK3 信号通路具有协同效应。JAK3/BTK-IN-5 对 JAK3 激酶和/或 BTK 相关疾病具有潜在的研究价值。 | |||
T62716 | BTK-IN-10 | ||
BTK-IN-10 是一种 BTK 的有效抑制剂,能够作用于野生型 BTK (IC50<5 nM) 或突变型 BTK (C481S) (IC50<5 nM)。 | |||
T39081 |
A 410099.1, amine-Boc
|
||
A-410099.1, also known as amine-Boc, serves as a functionalized IAP ligand instrumental in the synthesis of PROTACs, including those targeting BTK (specifically PROTACs 4 and 5). | |||
T79292 |
PROTAC BTK Degrader-5
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
PROTACBTK Degrader-5 (compound 3e) 是一种BTK选择性降解剂,其在JeKo-1细胞中的DC50为7.0 nM。该化合物对CRBN新基态显示出无脱靶活性,且对淋巴瘤细胞表现出抗增殖效果,适用于恶性淋巴瘤的研究1。 | |||
T79812 |
BTK-IN-27
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
BTK-IN-27(示例8)作为一种BTK抑制剂,具有高效的IC50值为0.2 nM。在TMD8细胞中,该化合物展现出显著的抗增殖能力,IC50值低于5 nM。BTK-IN-27适用于癌症、淋巴瘤、白血病及免疫性疾病研究领域。 | |||
T39919 |
A 410099.1, amine-Boc hydrochloride
|
||
A 410099.1, amine-Boc hydrochloride, serves as a functionalized IAP (Inhibitor of Apoptosis Proteins) ligand instrumental in the synthesis of PROTACs (Proteolysis Targeting Chimeras), notably those targeting BTK (Bruton's Tyrosine Kinase), including PROTACs 4 and 5. |